trending Market Intelligence /marketintelligence/en/news-insights/trending/HrRI1BqG8Cj4L8P5Y2lThQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sanofi, Regeneron's Praluent lowers cholesterol in diabetics, trial data shows

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sanofi, Regeneron's Praluent lowers cholesterol in diabetics, trial data shows

Sanofi and Regeneron Pharmaceuticals Inc.'s Praluent met the primary endpoints in two phase 3b/4 studies of patients with diabetes and hypercholesterolemia.

Praluent reduced low-density lipoprotein cholesterol, or LDL-C, by 48.2% from baseline when administered on top of maximally tolerated doses of statins and was superior to usual care in reducing non-high-density lipoprotein cholesterol, or non-HDL-C, in the trials.

Approximately 80% patients reached their LDL-C goals with Praluent 75-milligrams every two weeks under the trial, which is also the recommended starting dose for the drug.

In a previously reported study, Praluent 150 milligrams on top of maximally tolerated doses statins reduced LDL-C by 60% from baseline in diabetic patients at week 24.

The drug was well-tolerated in the patient populations and the most common adverse effects were common cold symptoms, urinary tract infections and diarrhea, among others.

Praluent inhibits the binding of proprotein convertase subtilisin/kexin type 9, or PCSK9, to the LDL receptor, which increases the number of available LDL receptors on the surface of liver cells, resulting in lower LDL-C levels in the blood.

The positive results from the Odyssey trials "provide valuable information on the efficacy and safety of Praluent" on diabetic patients who are at high risk of cardiovascular diseases, said Lawrence Leiter, chair of the Odyssey Steering Committee and director of the Lipid Clinic at the Li Ka Shing Knowledge Institute at St. Michael's Hospital, University of Toronto, Canada.